We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




A Fifth of Stroke Survivors Fail to Take Antithrombotic Medication

By HospiMedica International staff writers
Posted on 28 Dec 2009
A new study claims that approximately 20% of stroke survivors are not taking antithrombotic agents such as aspirin, despite doctor's recommendations. More...


Researchers at the University of California, Los Angeles (UCLA; USA) analyzed data compiled from seven U.S. annual medical-expenditure panel survey (MEPS) data sets, from 2000 to 2006, in which 4,168 people reported having had a stroke. The study authors then looked at the participant's use of antithrombotic agents, which include aspirin, other antiplatelet medications, and anticoagulants. Pooling the results across the seven years, the researchers found that 75% of the stroke survivors were using an antithrombotic agent, with 66% reporting taking antiplatelet medication, and 57% taking aspirin. After excluding those individuals who reported not taking aspirin because it was unsafe for them, the researchers calculated that 81% were actually using their antithrombotic agents. The researchers also found that individuals who were younger, female, or of Hispanic origin were less likely to take their medication. The findings were published in the January 2010 issue of the American Journal of Preventive Medicine.

"Even though use of prescription antiplatelet medications is rising, aspirin remains the predominant antithrombotic agent used for secondary stroke prevention. There were no improvements in overall use of antithrombotic agents over the 7-year period,” said lead author assistant professor of neurology Eric Cheng, M.D., M.S. "Use of aspirin, prescription antiplatelet agents, and use of any antiplatelet agent increased over the study period, but after dropping the first 2 years, no temporal trend was detected, indicating that temporal changes in usage of these agents had plateaued.”

The annual MEPS survey contains data on use of both aspirin and other prescription medications. Each year, a MEPS panel is drawn from respondents from the previous year's U.S. National Health Interview Survey, a representative sample of the U.S. civilian noninstitutionalized population, with oversampling of minority populations and households with low family income.

Related Links:
University of California, Los Angeles


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.